Indegene today unveiled its ambitious expansion of the Consulting Practice, reaffirming its ongoing commitment to enable life sciences organizations to navigate value and risk in large transformation efforts, in a complex, technology-driven world...
Iberia Pharmaceuticals, a leading name in skincare, has launched KeyCi, a science-backed skincare brand designed for modern consumers aged 18–45. KeyCi offers high-performance, dermatologically tested products that are vegan, cruelty-free...
Strides Pharma Science Limited today announced that one of its step-down wholly owned subsidiary will market the world’s first WHO-prequalified generic version of subcutaneous depot medroxyprogesterone acetate (DMPA-SC) in Africa, strengthening...
Pfizer has disclosed positive Phase 3 results from the HER2CLIMB-05 trial, which is an important advancement for patients with HER2-positive (HER2+) metastatic breast cancer (MBC)...
Novo Nordisk has made a significant advance in the rare disease sector by signing a definitive asset purchase and license agreement with Omeros Corporation to acquire its clinical-stage MASP-3 inhibitor zaltenibart...
BASF has introduced Lutavit A/D3 1000/200 NXT, an advanced vitamin formulation that integrates vitamins A and D3 into one microencapsulated product. Representing BASF’s reentry into the market, this new solution offers enhanced efficiency, ease of us
Fortis Hospital, Mulund, has inaugurated its Fortis Cancer Institute and Institute of GastroSciences, marking a significant milestone in its mission to deliver comprehensive, patient-first healthcare.
Aragen, a prominent global contract research, development, and manufacturing organization (CRDMO), has announced the appointment of Neeraj Garg as Chief Executive Officer of its Discovery Solutions division
Biocon Biologics Ltd. (BBL), a leading global biosimilars company and subsidiary of Biocon Ltd., announced today the extension of its strategic collaboration with Civica, Inc. to include a new medicines, Insulin Glargine, to improve patient access...
Eli Lilly and Company has reported positive topline results from its Phase 3 ACHIEVE-2 and ACHIEVE-5 clinical trials evaluating orforglipron in adults with type 2 diabetes
.jpg)
, CDSCO.jpg "Fostering a Quality Culture in the Pharmaceutical Industry")